The NDA resubmission is supported by results from the successful Phase 3 PIVOT-PO trial (NCT number – NCT06059846). The trial was stopped early for efficacy in May, 2025 following a planned interim ...
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated ...
Remedy's Nutrition® maintains the highest quality standards in producing this premium multivitamin formula. Unlike mass-produced supplements, each batch undergoes rigorous testing for purity, potency, ...
PL-16 is a metered-dose intranasal spray containing a hydrogel formulation composed of biodegradable polymers, together with standard excipients. Upon application, PL-16 forms a thin, muco-adhesive ...
Total national coverage footprint for PENFS increases to roughly 100 million covered lives ...
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application ...
This change recognizes the medical use of cannabis and reduces barriers to research. MediPharm Labs is well positioned to benefit from this milestone through its FDA site registration, Drug ...
Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering ...
MARKHAM, Ontario, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed acquisition of a ...
NDT Pharmaceuticals, Inc.’s (OTC: NDTP) wholly-owned subsidiary Good Salt Life, Inc., a pioneer in innovative surface treatment and biosecurity solutions, announces a groundbreaking achievement with ...
By incorporating OpenAI-powered LLM tooling into its research and analytics stack, EMJX aims to strengthen multi-cycle strategy evaluation, dynamic volatility-management modeling, and decision support ...
The collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental drugs called kRas inhibitors Melbourne, Australia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Amplia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback